The AHA today urged the Drug Enforcement Administration to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing concern that the agency’s proposal to reduce 2020 production quotas for five opioid controlled substances would exacerbate shortages of injectable opioid medications. “Beyond the negative impact on patient care, inadequate supplies of these drugs also creates burdensome and potentially dangerous workarounds for health care staff who must use alternative, often suboptimal products,” AHA wrote. Among other actions, AHA continued to recommend that DEA routinely consult with the Food and Drug Administration when establishing and adjusting quotas. “Obtaining [national drug] shortage data from the FDA will help to ensure that the DEA’s annual production quotas are set to provide adequate supplies for the United States’ legitimate needs,” the association said.

Related News Articles

Headline
The American Society for Health Care Engineering July 28 announced the recipients of its annual member awards during the 2025 Health Care Facilities Innovation…
Headline
AHA Chair-elect Marc Boom, M.D., president and CEO of Houston Methodist, and AHA Immediate-past Chair Joanne Conroy, M.D., president and CEO of Dartmouth…
Headline
Fairview Health Services, a Minneapolis-based nonprofit health system of 10 hospitals and medical centers serving the greater Twin Cities metro area and north-…
Headline
The Rural Hospital Excellence in Innovation Award honors rural hospitals that are leading the way in innovative, sustainable and community-centered care. If…
Headline
AHA’s Circle of Life Award celebrates innovation in palliative and end-of-life care and seeks to provide best practices and models for the field. Programs and…
Headline
The AHA encourages hospitals and health systems that are committed to leadership and innovation in improving quality and advancing health to apply for its 2026…